MedTrace Logo

Families-At-risk for Interstitial Lung Disease Study

NCT03641742 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2023-11-18

Study results available
· View outcomes & findings →

Summary

The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fibrotic ILD with a median survival of only 3.8 years, affects nearly 0.5% of older adults in the U.S. While pirfenidone and nintedanib slow the progression of IPF, neither reverses fibrosis nor prevents progression of the disease,and no studies to date have tested interventions that prevent the development of fibrotic ILDs.

Conditions

Sponsors & Collaborators

  • University of Washington

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • University of Iowa

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Columbia University

    lead OTHER

Principal Investigators

  • Christine Garcia, MD, PhD · Columbia University

Eligibility

Min Age
35 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2020-02-11
Completion
2023-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641742 on ClinicalTrials.gov